FAQs
What are the deliverables of a standard lead development project?
A lead development project at QVQ is always custom-made to meet the needs of your project. Often included are the delivery of single-domain antibody phagemid libraries, masterplates of monoclonal antibodies, including individual sequences, and delivery of 0.2 mg purified material of 10-12 lead candidates accompanied with experimental data.
Do you sacrifice the animals after immunization?
No, immunizations are done by accredited partners, and we only use a small volume of blood for serum titration and RNA extraction of PBMCs. Animals are routinely reused for new campaigns after a resting period and are not sacrificed for the purpose of antibody development projects.
How does the “no cure, no pay” work at QVQ?
A project is divided into work packages led by a dedicated project manager. Together with the customer, it is decided whether the work package has been delivered. If not, QVQ will not invoice this work package. Thus, if no specific single-domain antibodies against the target of interest are found, the panning and selection work package will not be invoiced.
What is the success rate of lead panel antibody delivery?
Since QVQ works with a “no cure, no pay” policy, we make the effort to get high-quality antibodies out of each project. This means that if we receive good-quality immunogens and we use two animals to avoid the occasional bad responder, the success rate is >95%.
Who owns the IP of the project?
All intellectual property corresponding to the lead development project or the production, purification, and characterization of single-domain antibodies is transferred to the customer and is fully owned by the customer to allow protection and further development of the molecules.